AbbVie (ABBV) Gains from Investment Securities (2016 - 2026)

AbbVie (ABBV) has reported Gains from Investment Securities for 11 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gains from Investment Securities fell 45.69% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $6.1 billion, a 2.34% increase from a year earlier, with the FY2025 full-year figure at $6.5 billion, up 72.24% from the prior year.
• Gains from Investment Securities was $1.5 billion for Q2 2026 at AbbVie, down from $2.4 billion in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $2.8 billion in Q2 2025 and troughed at -$748.0 million in Q1 2022.
• A 5-year average of $1.2 billion and a median of $1.5 billion in 2024 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities sank 318.37% in 2022 and surged 16850.0% in 2024, its largest moves.
• Over 5 years, Gains from Investment Securities stood at $2.1 billion in 2022, then fell by 19.77% to $1.7 billion in 2023, then slumped by 83.55% to $279.0 million in 2024, then jumped by 403.94% to $1.4 billion in 2025, then gained by 7.97% to $1.5 billion in 2026.
• The last three Gains from Investment Securities figures came in at $1.5 billion (Q2 2026), $2.4 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.